The National Institutes of Health, which historically has funded the research behind almost every drug on the market, this month announced that it would shift money that had been spent studying mRNA vaccines to pay for a $500 million grant to study a universal vaccine using traditional, non-mRNA technology. Jay Bhattacharya, a leading critic of the Covid response and the new director of the N.I.H., called it a “paradigm shift.”
The National Institutes of Health, which historically has funded the research behind almost every drug on the market, this month announced that it would shift money that had been spent studying mRNA vaccines to pay for a $500 million grant to study a universal vaccine using traditional, non-mRNA technology. Jay Bhattacharya, a leading critic of the Covid response and the new director of the N.I.H., called it a “paradigm shift.”